Department of Pathology, Henan Provincial People's Hospital, People's Hospital of Zhengzhou University, Zhengzhou, China.
Department of Thyroid Surgery, the Second Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Cancer Control. 2024 Jan-Dec;31:10732748241284952. doi: 10.1177/10732748241284952.
APOBEC-1 complementation factor (A1CF) and Apolipoprotein B mRNA editing enzyme, catalytic polypeptide-1 (APOBEC-1) constitute the minimal proteins necessary for the editing of apolipoprotein B (apoB) mRNA in vitro. Unlike APOBEC-1 and apoB mRNA, the ubiquitous expression of A1CF in human tissues suggests its unique biological significance, with various factors such as protein kinase C, thyroid hormones, and insulin regulating the activity and expression of A1CF. Nevertheless, few studies have provided an overview of this topic.
We conducted a literature review to describe the molecular mechanisms of A1CF and its relevance to human diseases.
In the PubMed database, we used the keywords 'A1CF' and 'APOBEC-1 complementation factor' to collect peer-reviewed articles published in English from 2000 to 2023. Two authors independently reviewed the articles and reached the consensus.
After reviewing 127 articles, a total of 61 articles that met the inclusion criteria were included in the present review. Studies revealed that A1CF is involved in epigenetic regulation of reproductive cells affecting embryonic development, and that it is closely associated with the occurrence of gout due to its editing properties on apoB. A1CF can also affect the process of epithelial-mesenchymal transition in renal tubular epithelial cells and promote liver regeneration by controlling the stability of IL-6 mRNA, but no influence on cardiac function was found. Furthermore, increasing evidence suggests that A1CF may promote the occurrence and development of breast cancer, lung cancer, renal cell carcinoma, hepatocellular carcinoma, endometrial cancer, and glioma.
This review clarifies the association between A1CF and other complementary factors and their impact on the development of human diseases, aiming to provide guidance for further research on A1CF, which can help treat human diseases and promote health.
载脂蛋白 B mRNA 编辑酶催化多肽 1（APOBEC-1）互补因子（A1CF）和载脂蛋白 B（apoB）mRNA 编辑酶构成了体外编辑 apoB mRNA 所必需的最小蛋白。与 APOBEC-1 和 apoB mRNA 不同，A1CF 在人体组织中的广泛表达表明其具有独特的生物学意义，多种因素如蛋白激酶 C、甲状腺激素和胰岛素调节 A1CF 的活性和表达。然而，很少有研究对这一主题进行全面概述。
我们进行了文献综述，以描述 A1CF 的分子机制及其与人类疾病的相关性。
在 PubMed 数据库中，我们使用关键词“A1CF”和“APOBEC-1 互补因子”收集了 2000 年至 2023 年发表的英文同行评议文章。两位作者独立审查文章并达成共识。
在审查了 127 篇文章后，共有 61 篇符合纳入标准的文章纳入本综述。研究表明，A1CF 参与生殖细胞的表观遗传调控，影响胚胎发育，由于其对 apoB 的编辑特性，与痛风的发生密切相关。A1CF 还可以通过控制 IL-6 mRNA 的稳定性影响肾小管上皮细胞的上皮-间充质转化过程，并促进肝再生，但对心脏功能没有影响。此外，越来越多的证据表明，A1CF 可能促进乳腺癌、肺癌、肾细胞癌、肝细胞癌、子宫内膜癌和神经胶质瘤的发生和发展。
本综述阐明了 A1CF 与其他互补因子的关联及其对人类疾病发展的影响，旨在为进一步研究 A1CF 提供指导，有助于治疗人类疾病和促进健康。
